Strategic objectives

Edvince is based on vascular research and operates at the intersection of advanced neuroscience and needs-driven drug development. The starting point is clear: there is an urgent medical need for new, effective treatments for stroke and cerebral haemorrhage, as current standard treatments are insufficient to reduce mortality and long-term disability. 

Edvince’s drug candidate can be used for secondary brain damage resulting from subarachnoid haemorrhage (SAH), stroke and cerebral ischaemia following a heart attack. Initially, the company has a clinical focus on SAH. 

Through the further development of new products, the company will be able to develop several drug treatments for other stroke indications. Edvince has commenced work on an intravenous formulation to capitalise on the breadth of the company’s commercial opportunities.

To maximise the efficiency, flexibility and visibility of its assets, Edvince’s R&D operations will be organised in 2026 under a Hub & Spoke structure, where the subsidiaries manage the relevant therapeutic areas and the parent company Edvince handles matters such as financing and business development for the subsidiaries.

Each subsidiary will conduct indication-specific drug development, whilst the scientific basis, formulation, manufacturing and regulatory activities are shared between subsidiaries – which creates strong synergies, simplifies parallel development and increases the potential for business development activities. All of the subsidiaries’ drug candidates are based on inhibition of the MEK/ERK signalling pathway, a key mechanism involved in the development of brain damage resulting from oxygen deprivation. 
Edvince’s business model has been designed for flexibility and clear value creation in every phase of development. By combining scientific advances, an orphan drug strategy, a low-cost structure and a broad pipeline with a common platform, Edvince is well positioned to create lasting value for patients, the healthcare sector and investors.

Strategic objectives at a glance:

• Conduct a Phase 2b study in SAH
• Advance projects aimed at developing drug candidates for other stroke indications into the clinical phase
• Business development with the aim of securing partnerships, or alternatively out-licensing/sales within 24 months of the start of the Phase 2b study in SAH